TAA-05 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TAA-05’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAA-05 overview
TAA-05 is under development for the treatment of relapsed and refractory acute myelocytic leukemia. The drug candidate comprises of autologous T cells genetically engineered to express a chimeric antigen receptor acts by targeting FLT3 autologous chimeric antigen receptor T cells. It is administered through intravenous route.
PersonGen BioTherapeutics (Suzhou) overview
PersonGen BioTherapeutics (Suzhou) (PersonGen) is a biotechnology company focused on developing CAR-related therapies, analytical antibodies, novel CAR-T therapeutics, and allogeneic cellular therapies. PersonGen is headquartered in Suzhou, Jiangsu, China.
For a complete picture of TAA-05’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.